logo

For the Inventor, By the Inventor

Berkeley, CA, United States of America

Caribou Biosciences, Inc.


USPTO Granted Patents = 60



Trademarks = 5

Forward Citations = 546

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Andrew Paul May (39 out of 71 patents)

silverMedal Paul Daniel Donohoue (34 out of 47 patents)

bronzeMedal Rachel E Haurwitz (12 out of 16 patents)

4.  Jennifer A Doudna (9 out of 145 patents)

5.  James M Berger (9 out of 9 patents)

6.  Matthew Merrill Carter (9 out of 15 patents)

7.  Lijun Wu (8 out of 26 patents)

8.  Vita Golubovskaya (8 out of 23 patents)

9.  Peter Sean Cameron (8 out of 9 patents)

10.  John Van Der Oost (7 out of 22 patents)

11.  Sanne Eveline Klompe (7 out of 9 patents)

12.  Samuel Henry Sternberg (6 out of 9 patents)

13.  Stan Johan Jozef Brouns (5 out of 5 patents)

14.  Megan Van Overbeek (2 out of 2 patents)

15.  Daniël Christianus Swarts (2 out of 2 patents)


Core Competencies:
CRISPR
Nucleic Acids
Antibody
CAR-T Cells
RNA
DNA Repair
Cascade Components
Polynucleotides
Target Cleaving
Engineered Cells
Ribonucleoproteins
Cell Engineering

60 patents:

1. 12686865 - Compositions and methods of nucleic acid-targeting nucleic acids (2026-07-21),
2. 12644138 - DUAL GUIDE CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE (2026-06-02),
3. 12492264 - ANTI-ROR1 ANTIBODY AND ROR1-TARGETING ENGINEERED CELLS (2025-12-09),
4. 12435152 - Humanized BCMA antibody and BCMA-CAR-T cells (2025-10-07),
5. 12416045 - Method of capturing CRISPR endonuclease cleavage products (2025-09-16),
6. 12227776 - Engineered cascade components and cascade complexes (2025-02-18),
7. 11939604 - Modified cascade ribonucleoproteins and uses thereof (2024-03-26),
8. 11932703 - Anti-ROR1 antibody and ROR1-targeting engineered cells (2024-03-19),
9. 11555181 - Engineered cascade components and cascade complexes (2023-01-17),
10. 11505808 - Engineered nucleic acid-targeting nucleic acids (2022-11-22),
11. 11472884 - Humanized BCMA antibody and BCMA-CAR-T cells (2022-10-18),
12. 11459588 - Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides (2022-10-04),
13. 11312953 - Compositions and methods of nucleic acid-targeting nucleic acids (2022-04-26),
14. 11299549 - Humanized BCMA antibody and BCMA-CAR-T cells (2022-04-12),
15. 11236364 - CRISPR hybrid DNA/RNA polynucleotides and methods of use (2022-02-01),
Company Overview
Caribou Biosciences, Inc. is a pioneering biotechnology company based in Berkeley, California, specializing in CRISPR technology. The organization focuses on developing innovative solutions in gene editing, leveraging its expertise in nucleic acids, RNA, and DNA repair mechanisms. Caribou's research extends to the creation of advanced therapeutic applications, including CAR-T cell therapies and antibody development, positioning the company at the forefront of genetic engineering and precision medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

60 Patents

#11 in Berkeley, CA

#1,405 in California

#5,999 in US

#12,094 in the World

Berkeley, CA (US)
Berkeley, CA, United States of America

Caribou Biosciences, Inc.

Forward Citations = 546

21 inventors:

goldMedal Andrew Paul May (39 out of 71 patents)

silverMedal Paul Daniel Donohoue (34 out of 47 patents)

bronzeMedal Rachel E Haurwitz (12 out of 16 patents)

4.  Jennifer A Doudna (9 out of 145 patents)

5.  James M Berger (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Caribou Biosciences, Inc.. Retrieved from https://idiyas.com/company/caribou-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…